BPMC - ブル―プリント・メディシンズ （Blueprint Medicines Corporation） ブル―プリント・メディシンズBPMCのチャート
BPMCの企業情報
| symbol | BPMC |
|---|---|
| 会社名 | Blueprint Medicines Corp （ブル―プリント・メディシンズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ブループリント・メディシンズ（Blueprint Medicines Corporation）はバイオ医薬品会社である。同社は、異常なキナーゼ活性化によって遺伝的に定義された疾患患者を中心とする。同社は適切な治療オプションがない患者に臨床的応答を提供する薬剤候補を作ることに焦点を当てる。同社は癌と遺伝病における小分子薬物パイプラインを開発した。薬剤候補のBLU-285は、エクソン17突然変異を含むKIT、及びD842V突然変異を含むPDGFRaを対象とする。これらの突然変異は、胃腸間質腫瘍（GIST）および全身性肥満細胞症（SM）を含む癌および増殖性障害の原因である受容体チロシンキナーゼを活性化する。薬物候補BLU-554は、肝細胞癌の一般的なタイプである肝細胞癌（HCC）を有する患者の定義されたサブセットにおいて活性化されるキナーゼであるFGFR4を対象とする。同社は突然変異または転座によって活性化された受容体チロシンキナーゼであるRETを対象とする薬剤候補のBLU-667の開発に従事している。 ブル―プリント・メディシンズは米国のバイオ医薬品会社。がん分子標的治療薬やキナ―ゼ阻害剤の開発を行う。異常なキナ―ゼ活性化によって発症するゲノム的に定義された疾患向け治療薬の開発に従事する。同社の「BLU-285」は、全身性肥満細胞症で胃腸管の消化管間質腫瘍や骨髄増殖性障害を有する患者向けに開発された。本社はマサチュ―セッツ州ケンブリッジ。 Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. |
| 本社所在地 | 45 Sidney Street Suite 200 Cambridge MA 02139 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-374-7580 |
| 設立年月日 | 39722 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 149人 |
| url | www.blueprintmedicines.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bpmc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -174.38100 |
| 終値（lastsale） | 69.43 |
| 時価総額（marketcap） | 3047125232.76 |
| 時価総額 | 時価総額（百万ドル） 311.137 |
| 売上高 | 売上高（百万ドル） 52.08900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2398.373 |
| 当期純利益 | 当期純利益（百万ドル） -170.32700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Blueprint Medicines Corp revenues increased from $11.7M to $42.4M. Net loss increased 36% to $83.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and development increase of 71% to $101.2M (expense) Other General and administrative increase of 63% to $16.2M (expense). |
BPMCのテクニカル分析
BPMCのニュース
Blueprint Medicines PT Lowered to $115 at Raymond James 2022/08/02 16:51:02 Investing.com
https://www.investing.com/news/pro/blueprint-medicines-pt-lowered-to-115-at-raymond-james-432SI-2860818
Blueprint Medicines Corporation''s (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call Transcript 2022/08/02 15:31:04 Seeking Alpha
Blueprint Medicines Corporation (NASDAQ:NASDAQ:BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 A.M.
BPMC stock climbs ahead of key data readout despite 2Q miss (NASDAQ:BPMC) 2022/08/02 14:52:27 Seeking Alpha
Shares of oncology focused Blueprint Medicines (BPMC) surged ~13% in the morning hours Tuesday despite lower-than-expected financials for 2Q 2022 as management outlined plans to report…
Blueprint Medicines: Q2 Earnings Insights 2022/08/02 11:39:56 Benzinga
Blueprint Medicines (NASDAQ: BPMC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus … Full story available on Benzinga.com
Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance 2022/08/02 11:08:25 Seeking Alpha
Blueprint Medicines press release (BPMC): Q2 GAAP EPS of -$2.68 misses by $0.45.Revenue of $36.5M (+33.7% Y/Y) misses by $1.11M.As of June 30, 2022, cash, cash equivalents…
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 2021/03/10 21:30:00 PR Newswire
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the company's precision oncology and hematology portfolio at the American Association for…
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis 2021/03/03 13:00:00 PR Newswire
CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of…
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines By Investing.com 2021/02/19 09:13:16 Investing.com
Robert W. Baird Stick to Their Buy Rating for Blueprint Medicines
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results 2021/02/17 12:00:00 PR Newswire
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. "Last year was transformational for Blueprint Medicines, with four…